Elvitegravir
From Wikipedia, the free encyclopedia
 |
|
 |
|
| Systematic (IUPAC) name | |
|---|---|
| 6-[(3-Chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid | |
| Identifiers | |
| CAS number | 697761-98-1 |
| ATC code | none |
| PubChem | 5277135 |
| Chemical data | |
| Formula | C23H23ClFNO5 |
| Mol. mass | 447.883 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Elvitegravir (EVG) is an investigational new drug for the treatment of HIV infection. It acts as an integrase inhibitor. It is undergoing Phase III clinical trial[1] conducted by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2005.[2][3][4]
According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.[5]
[edit] References
- ^ Gilead Press Release Phase III Clinical Trial of Elvitegravir July 22, 2008
- ^ Gilead Press Release Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor March 22, 2005
- ^ Shimura K, Kodama E, Sakagami Y, et al. (2007). "Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137)". J Virol 82: 764. doi:. PMID 17977962. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=17977962.
- ^ Stellbrink HJ (2007). "Antiviral drugs in the treatment of AIDS: what is in the pipeline ?". Eur. J. Med. Res. 12 (9): 483–95. PMID 17933730.
- ^ Thaczuk, Derek and Carter, Micheal. ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents Aidsmap.com. 19 Sept. 2007.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
